Monoamine oxidase (MAO) exists as two isoenzymes and plays a central role in the metabolism of monoamine neu rotransmitters. In this study we compared the neurochemi cal phenotypes of previously described subjects with geneti cally determined selective lack of MAO-A or a lack of both MAO-A and MAO-B with those of two subjects with a pre viously described X chromosome microdeletion in whom we now demonstrate selective MAO-B deficiency. Mapping of the distal deletion breakpoint demonstrates its location in intron 5 of the MAO-B gene, with the deletion extending proximally into the Norrie disease gene. In contrast to the borderline mental retardation and abnormal behavioral phenotype in subjects with selective MAO-A deficiency and the severe mental retardation in patients with combined MAO-A/MAO-B deficiency and Norrie disease, the MAO-B-deficient subjects exhibit neither abnormal behavior nor mental retardation. Distinct neurochemical profiles charac terize the three groups of MAO-deficient patients. In MAO-A-deficient subjects, there is a marked decrease in deaminated catecholamine metabolites and a concomitant marked elevation of O-methylated amine metabolites. These neuro chemical changes are only slightly exaggerated in patients with combined lack of MAO-A and MAO-B. In contrast, the only biochemical abnormalities detected in subjects with the MAO-B gene deletion are a complete absence of platelet MAO-B activity and an increased urinary excretion of phenylethylamine. The differences in neurochemical profiles indicate that, under normal conditions, MAO-A is consider ably more important than MAO-B in the metabolism of bio genic amines, a factor likely to contribute to the different clinical phenotypes. (J. Clin. Invest. 1996. 97:1010-1019.)
Introduction
Monoamine oxidase (MAO),1 an enzyme that plays a crucial role in the metabolic degradation of biogenic amines, exists in two functional forms: MAO-A and MAO-B (1-3). The two isoenzymes have different substrate and inhibitor specificities and are encoded by two genes on the short arm of the X chro mosome (4) .
Combined loss of MAO-A and MAO-B activity (MAO-AB) has been described in some patients with an X chromo some deletion that includes not only the Norrie disease gene but also the MAO-A and MAO-B genes (5) (6) (7) (8) (9) . In addition to the blindness, hearing loss, and variable mental retardation that characterize Norrie disease (10) , patients with the addi tional deletion of both MAO genes show profound mental re tardation, autistic-like behavior, atonic seizures, altered pe ripheral autonomic function, and profound alterations in biogenic amine metabolism (5, 6, 8) . More recently, selective loss of MAO-A activity due to a point mutation in exon 8 of the MAO-A gene was described in a Dutch kindred (11, 12) . In this kindred, selective MAO-A deficiency was associated with a clinical phenotype characterized by borderline mental retardation and impaired impulse control, including a propen sity towards stress-induced aggression.
Understanding the consequences of genetic deficiencies of MAO isoenzymes requires an understanding of the role of these enzymes in the metabolism of biogenic amines. In addi tion to inactivating catecholamines and their O-methylated metabolites, MAO deaminates other biogenic amines includ ing 5-hydroxytryptamine (5-HT) and the trace amines phenylethylamine, m-tyramine, and p-tyramine (13) . The catechol amines and their deaminated metabolites are also subject to O-methylation by catechol-0-methyltransferase (COMT). MAO and COMT, in combination with alcohol dehydroge nase, are responsible for the production of a wide range of cat echolamine metabolites, which for the purpose of this study can be divided into two groups: deaminated metabolites and O-methylated amine metabolites (Fig. 1) .
The redundant nature of catecholamine metabolism en ables one pathway to compensate for blockade of the other, so that reduced or absent activity of MAO leads to a decrease in production of deaminated metabolites and an increase in that of O-methylated amine metabolites (14, 15) . Thus, simulta neous measurements of these metabolites are useful for neuro chemical phenotyping of patients with disorders of catechol amine metabolism (16).
The relative roles of COMT and MAO in the metabolic degradation of catecholamines are well established; on the other hand, those of the isoenzymes of MAO are not clear but are important for understanding the basis of therapeutic inter ventions involving specific inhibition of one or the other of the two MAO isoenzymes. Additionally, establishing the relative roles of MAO-A and MAO-B may also provide insight into how neurochemical alterations associated with deficiencies of the two isoenzymes give rise to clinical syndromes.
In the present study, we report on two subjects with a hith erto undescribed selective deficiency of MAO-B due to a mi crodeletion of the X chromosome, extending from the Norrie disease gene to within the MAO-B gene (17) . For comparison, the neurochemical characteristics of previously described pa tients with combined MAO-AB deficiency and selective MAO-A deficiency are reported in greater detail, including a comprehensive analysis of plasma catecholamine metabolites ( Fig. 1 ). These comparisons enabled examination of the rela tive roles of MAO-A and MAO-B in the metabolic degrada tion of catecholamines and other biogenic amines, including 5-HT and the trace amines.
Methods
Subjects. Two brothers (ages: 29 and 31 yr) with a complete selective loss of MAO-B activity due to a microdeletion of the Norrie disease and MAO-B genes participated in the study. Norrie disease, charac terized by blindness, was diagnosed at the ages of 5 and 18 mo. Pro gressive hearing loss due to cochlear degeneration was noticed in ad olescence in these subjects. Two male members (ages: 24 and 34 yr) of an unrelated Dutch family with a complete selective deficiency of MAO-A were also included in this study. Affected males in this fam ily have a point mutation of the MAO-A gene and are characterized clinically by borderline mental retardation and impaired impulse con trol (11, 12) , In addition, the study included five male subjects (age: 12-23 yr) from three different families, with a microdcletion of the X chromosomc, including the Norrie disease gene and the MAO-A and MAO-B genes (5-9). These latter subjects are characterized clinically by blindness and profound mental retardation. 29 males aged 21-55 yr (m ean±SD: 35±9 yr) served as a refer ence group for measurements of plasma catecholamincs and metabo lites. Subjects were not taking any medications and were all in good health as determined by a negative medical h is tory and a normal physical examination. These subjects were enlisted for study at two different institutions, The Clinical Center, National Institutes of Health (NIH), and the St. Radboud University Hospital. All proce dures were approved by the appropriate review committees, and in formed consent was obtained for all studies.
Procedures. Baseline venous blood samples were drawn after 15 min of rest, and plasma and piatelet-rich plasma were separated by centrifugation at 4°C. Samples of plasma and platelet-rich plasma were stored at -80°C until assayed for concentrations of catechol amines, metabolites, and 5-HT (8) , and activities of platelet MAO-B and plasma amine oxidase. 24-h urine samples were collected and acidified to pH 2-3, and 20-ml aliquots were stored at -25°C until as sayed. The two subjects with selective M AO-A deficiency received a simultaneous infusion of 3H-labeled NE and epinephrine (EPI) (l-2,5,6-[3H]NE, 40-60 Ci/mmol; L-N-methyl-[3H ]EPIf 65-75 Ci/ mmol [DuPont-New England Nuclear, 's Hertogenbosch, The N eth erlands]) to calculate forearm spillovers of NE and normetanephrine (18) . In these two subjects, a standardized tyramine infusion was also carried out to determine tyramine pressor sensitivity (19) . To com pare neurochemical abnormalities in MAO-deficient subjects with changes occurring after pharmacological inhibition of MAO, 11 male subjects (m ean±SD ages: 37±9 yr) with attention deficit hyperactiv ity disorder were studied before and after administration of deprenyl at a dose (60 mg daily for 6 wk) sufficient to inhibit both MAO-A and MAO-B (19) , DNA/genetic analysis. Genomic D N A in the two MAO-B-deficient subjects was isolated from peripheral blood as described previ ously (20) . DNA was digested by the restriction enzyme EcoRI, transferred to nylon membranes by Southern blotting, and hybridized to either 32P~labeled cosmid C5 (17) or to an MAO-B cDNA probe containing exons 3-15 (21) . Hybridizing bands were visualized by overnight exposure of the membrane to film (X-omat S; Eastman Kodak Co., Rochester, NY). Hybridizing fragments were assigned to specific MAO-B exons based on published data (22) . The detailed de scription of the genetic defects in the M A O -A -and M AO-AB-deficient subjects have been reported previously (5) (6) (7) (8) (10) (11) (12) .
Enzyme activities and platelet 5-HT. Platelet-rich plasma was pre pared by differential centrifugation using EDTA or acid citrate dex trose as anticoagulants. Platelet MAO-B and plasma amine oxidase activities were measured at the NIH, using 200 fiM methylene-[,4C]benzylamine (50 Ci/mmol; ICN Biomedicals Inc., Irvine, CA) as substrate (23) . Measurements of platelet MAO activity were also car ried out at the Academic Medical Center (Amsterdam, The Nether lands) using a fluorimetric method with kynuramine as substrate (24). sponding to specific exons are in- [9] [10] I p ^ f -dicated in the control. Exons 3-5 are lacking in the patient. Exon 6 is present, but the fragment size is altered, locating the breakpoint within intron 5.
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a Platelet concentrations of 5-HT were measured at the NIH as de scribed previously (5) . Plasma neurochemical assays. All assays of plasma catecholamines and their metabolites were carried out at the NIH. The catechol amines NE, EPI, and dopamine (DA); the deaminated catecholamine metabolites 3,4-dihydroxyphenylglycoI (DHPG) and dihydroxyphenylacetic acid (DOPAC); and the catecholamine precursor dihydroxyphenylalanine (DOPA) were extracted from 1-ml samples of plasma using alumina and quantified by liquid chromatography with electro chemical detection (25). The metanephrines-normetanephrine and metanephrine, O-methylated amine metabolites of NE and EPI, re spectively-were extracted from 2-ml samples of plasma using solidphase ion exchange columns and quantified by liquid chromatogra phy with electrochemical detection (26) . Timed collections of the catecholamine and metanephrine eluants leaving the electrochemical cell, followed by liquid scintillation spectroscopy, were used to deter mine plasma concentrations of 3H-labeled catecholamines and meta nephrines. Concentrations of sulfate-conjugated metanephrines were determined after deconjugation by incubation with sulfatase (Sigma Chemical Co., St. Louis, MO). Liquid chromatography with electro chemical detection was also used for measurement of the deaminated NE metabolite, 3-methoxy-4~hydroxyphenylglycol (MHPG), after extraction from plasma into ethylacetate (27). Concentrations of the DA metabolite, homovanillic acid (HVA), and of the final deami nated end-product of NE and EPI metabolism, vanillylmandelic acid (VMA), were measured by gas chromatography-mass spectrometry after ethylacetate extraction and derivatization with pentafluoropropionic anhydride (28) .
Urine neurochemical assays. Urine concentrations of catechol amines and their metabolites were determined at two centers: the NIH and the Academic Medical Center. These measurements were carried out using gas chromatography-mass spectroscopy at the NIH (8, 28) and liquid chromatography with fluorimetric detection at the Academic Medical Center (29, 30) . Urine concentrations of 5-HT were also measured at the latter center using liquid chromatography with fluorometric detection. Urine concentrations of trace amines (phenylethylamine, /?Myramine, and p-tyramine) were assayed at St. Elizabeth's Hospital (Washington, DC) by gas chromatography-mass spectroscopy as described previously (31). Urine concentrations of catecholamines and their metabolites are reported as total concentra tions (free and conjugated). Some of the urine data for the MAO-A B -and MAO-A-deficient subjects have been reported elsewhere (5,6,8,11).
Data analysis. The mean and SD of the plasma concentrations of catecholamines and metabolites in the 29 control subjects were calcu lated and served as the reference group for the tabulated data. Refer ence values for urine catecholamines and their metabolites were used from the original published methods. Differences between MAOdeficient subjects and control groups were tested by the Mann-Whit ney U lest. Within subject differences were determined using the Wilcoxon signed rank sum test. Differences were considered significant at P < 0,05 (two tailed). Ail values in the text are presented as mean±SEM , unless indicated otherwise.
Results

%
Clinical characteristics of the MA OS-deficient subjects. A gen eral physical examination of the two brothers with the MAO-B deficiency, including global neurological examination, was un remarkable. They have normal blood pressure and heart rate. They are blind and have impaired hearing as part of Norrie disease. Psychomotor development is normal. Both subjects have completed university degrees.
Delineation o f the X chromosome microdeletion. We have previously reported that the deletion in these two brothers with Norrie disease extends from within the Norrie disease gene on the proximal side to within the MAO-B gene (17) . Precise mapping of the deletion breakpoint was achieved by hybridization of the patients DNA to 13 cosmids derived from a 300-kb contig that encompasses the MAO-B and Norrie dis ease genes. In this way, the size of the deletion was estimated to be 150 kbp. Moreover, when cosmid C5 was used as a hy bridization probe on EcoRI-digested genomic DNA, four of the nine fragments were absent in the patient, and a putative deletion junction fragment of 2.5 kbp appeared ( Fig. 2, left) . Cosmid C5 had been shown previously to cover most of the MAO-B gene (17) .
Deletion of the 5' end of the MAO-B gene was confirmed by hybridizing the same Southern blot to a cDNA probe con taining exons 3-15 of the MAO-B gene. This experiment dem onstrated deletion of exons 3-5 and an altered size of the frag ment containing exon 6 ( Fig. 2, right) . Based on these results, the distal deletion breakpoint is located in intron 5, between tel I-50 kbp cen LÎ.28 exons 5 and 6 or possibly just within exon 6 ( Fig. 3) . Thus, the promoter, the transcription start site, and the first five exons that contain the DNA sequence encoding the first 159 amino acids of MAO-B are lacking in these patients. Documentation of MAO-B deficiency. Both assays of plate let MAO-B activity, carried out at separate centers using either benzylamine or kynuramine as substrates, indicated undetect able levels of MAO-B activity in the two subjects with deletion of the MAO-B gene (Table I) . Platelet MAO-B activity was also undetectable in patients with combined MAO-AB defi ciency, whereas it was normal in the subjects with selective MAO-A deficiency. The activity of plasma amine oxidase was normal in all three subject groups (Table I) .
Platelet 5-HT. The 5-HT content of platelets was within normal limits in the two subjects with MAO-B deficiency, whereas it was increased considerably in the groups with selec tive MAO-A and combined MAO-AB deficiencies (Table I) .
Plasma concentrations of catecholamines and metabolites. Plasma concentrations of NE and EPI were within the normal range in all MAO-deficient subjects (Table II) . Plasma con centrations of DA were also normal in the subjects with selec tive deficiencies of MAO-B or MAO-A, whereas they were higher in patients with the combined MAO-AB deficiency than in control subjects (0.19±0.06 vs 0.07±0.01 pmol/ml; P < 0.05). Plasma concentrations of free and sulfate-conjugated normetanephrine and metanephrine, the O-methylated amine metabolites of NE and EPI, were normal in MAO-B-deficient subjects, whereas both groups of MAO-A-and MAO-ABdeficient subjects showed considerable elevations above nor mal in plasma concentrations of free and sulfate-conjugated normetanephrine and sulfate-conjugated metanephrine (Table  II) . In contrast, all MAO-deficient subjects, apart from one MAO-AB-deficient patient (number 6), showed normal or only slightly elevated plasma concentrations of free metaneph rine. Thus, plasma concentrations of sulfate-conjugated meta nephrine in MAO-A-and MAO-AB-deficient subjects were elevated above mean concentrations of normal subjects more than concentrations of free metanephrine (4.5±0.53 vs 2.1 ± 0.7-fold increase; P < 0.03). Similarly, plasma concentrations of sulfate-conjugated normetanephrine showed larger eleva tions in MAO-A-and MAO-AB-deficient subjects than con centrations of free normetanephrine (13.2±3,0 vs 6.5±0.6-fold increase; P < 0.02). Increases in plasma concentrations of free and sulfate-conjugated normetanephrine were larger (P < 0.02) than those of metanephrine.
Plasma concentrations of DHPG, the deaminated metabo lite of NE and EPI, were normal in MAO-B-deficient sub jects, whereas they were reduced by > 95% in MAO-A sub jects and undetectable in four of the .five subjects with combined MAO-AB deficiency (Table II) . A similar pattern was observed for MHPG and VMA, the deaminated and O-methylated metabolites of NE and EPI; these metabolites were normal in MAO-B-deficient subjects, whereas they were reduced by 75-92% in the two MAO-A-deficient subjects and reduced further to > 93% in the subjects with the combined MAO-AB deficiency.
Since plasma concentrations of DHPG and sulfate-conju gated normetanephrine showed the largest reciprocal changes in MAO-AB-deficient subjects, the ratios of these metabolites were compared with those in normal subjects and patients re ceiving the MAO inhibitor, deprenyl ( Fig. 4 ). Ratios of plasma concentrations of sulfate-conjugated normetanephrine to DHPG were within the normal range in the MAO-B-deficient sub jects, whereas these ratios were elevated by ^ 100-fold in the ,2 loooo, « u, 1000. MAO-A-deficient subjects and by more than several thou sand-fold in all five subjects with the combined MAO-AB de ficiency. Similarly, in the subjects who received deprenyl, a 250% increase in conjugated normetanephrine and a 60% de crease in plasma concentrations of DFIPG resulted in an in crease in the ratio of these two metabolites.
The deaminated metabolites of DA, DOPAC, and HVA showed a less marked and more variable trend than that ob served for the deaminated metabolites of NE and EPI (Table  II) . Again, plasma concentrations of these metabolites were normal in the two MAO-B-deficient subjects but reduced by 53-60% in the MAO-A-deficient subjects. Plasma DOPAC and HVA tended to be reduced more in the combined MAO-AB-deficient subjects than in the two MAO-A-deficient sub jects, but there was considerable variability. In particular, one subject with combined MAO-AB deficiency showed normal concentrations of both DOPAC and HVA.
Plasma levels of DOPA, the catecholamine precursor, were normal in MAO-B-deficient subjects (7.65 and 7.54 nmol/li ter), but significantly lower in subjects with selective MAO-A and combined MAO-AB deficiencies than in control subjects (5.64±0.44 vs 8.55±0.40 nmol/liter, respectively; P < 0.01).
Urinary excretion o f catecholamines, catecholamine metab olites, 5-HT, and trace amines. The only abnormal neurochem ical finding in the MAO-B-deficient subjects was an increase in urinary phenylethylamine levels (Table III) , Urinary excre tion of the other trace amines, meta-and paratyramine, was normal, as was that of the catecholamines, their O-methylated and deaminated metabolites, and 5-HT.
In contrast to the MAO-B-deficient subjects, the two sub jects with a selective deficiency of MAO-A showed increased excretion of 5-HT, normetanephrine, and the O-methylated amine metabolite of DA, 3-methoxytyramine (11). These sub jects also showed decreased or low-normal urinary excretion of the deaminated metabolites, MHPG, VMA, and HVA. Ex cretion of all trace amines was within normal limits.
In subjects with the combined MAO-AB deficiency, the urinary excretion of catecholamines and their metabolites showed similar qualitative alterations as in subjects with the selective MAO-A deficiency but tended to be more variably disturbed (Table III) . In particular, excretion of HVA showed highly variable changes compared with other subject groups. Similar to the situation in plasma, urinary levels of DA were also increased in patients with combined MAO-AB deficien cies but not in those with selective deficiencies of either iso enzyme. Excretion of all trace amines was profoundly increased in patients with combined MAO-AB deficiency. In particular, excretion of phenylethylamine was increased substantially more in combined MAO-AB-deficient subjects than in selec tive MAOB-deficient subjects. Furthermore, whereas excre tion of the tyramine trace amines was normal in subjects with either selective deficiency of MAO-A or MAO-B, it was in creased considerably in subjects with the combined MAO-AB deficiency.
Forearm spillover of NE and normetanephrine in MAO-A deficiency. Use of the tracer-labeled NE and EPI isotope dilu tion technique indicated an increase in forearm spillover into plasma of normetanephrine in the two MAO-A-deficient sub jects (Table IV) . Forearm spillovers of normetanephrine from both circulating and locally released NE were increased. Fore arm spillover of NE was also increased in one of these subjects.
Tyramine sensitivity test. In one of the two MAO-A-defi cient subjects, systolic blood pressure was increased to the 30-mmHg end-point by an intravenous dose of tyramine of only 0.11 mg/min; this represents a dose less than one-tenth of that required in a control group of 11 patients with depression (19) , and comparable to that in patients treated with selective MAO-A and nonselective MAO inhibitors (32) , but about fourfold more than the end-point dose required in a juvenile patient with combined MAO-AB deficiency (5) . In the other MAO-A-deficient subject, the tyramine infusion had to be stopped prematurely at an infusion rate of 0.03 mg/min be cause of persisting oppressing pain in his chest. Systolic blood pressure had increased by 5 mmHg at this infusion rate.
Discussion
This is the first description of patients with a selective loss of MAO-B activity due to a disruption of the MAO-B gene on the X chromosome. This is also the first comprehensive report comparing neurochemical and clinical phenotypes in patients with selective deficiencies of MAO-A and MAO-B and com bined deficiencies of MAO-AB. The results demonstrate that the three groups of patients each display characteristic neuro- 
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chemical profiles that may contribute to the different clinical phenotypes of each group. Genotype and clinical phenotype of MAO-B deficiency pa tients. In addition to a partial deletion of the MAO-B gene, the gene for Norrie disease is also involved in the syndrome af fecting these two brothers. In fact, these patients were origi nally described as part of a previous study of Norrie disease that resulted in the cloning of the Norrie disease gene (17) . Al though these subjects show the characteristic features of Nor rie disease, namely early onset blindness and progressive hear ing loss, they show no signs of physical or mental impairment. In particular, no signs of mental retardation or behavioral dis turbances have been noted as are observed in patients with classical Norrie disease combined with MAO-AB deficiency (5) (6) (7) (8) or in subjects with selective MAO-A deficiency (11, 12) . Only a part of the MAO-B gene is deleted, but since this in cludes the DNA sequence encoding the first 159 amino acids of MAO-B, this is incompatible with any functional MAO-B activity. A complete and selective lack of MAO-B is docu mented by the undetectable levels of platelet MAO-B activity, determined by two different assay techniques, and is also reflected in the increased urinary phenylethylamine levels that are characteristically found with reduced MAO-B activ ity (33) .
Metabolic roles of MAO isoenzymes. Comparison of the se lective deficiencies of MAO-A and MAO-B and combined de ficiency of MAO-AB provides a unique insight into the meta bolic roles of the MAO isoenzymes in humans. This insight is not only important for interpreting the clinical consequences of MAO deficiency states, but also for understanding the basis of therapeutic interventions involving selective inhibition of MAO-A or MAO-B. Up until now, studies of the metabolic roles of MAO-A and MAO-B have been confined largely to pharmacological studies in animals or isolated tissues. Such studies are limited by a lack of completely selective MAO in hibitors as well as by difficulties in extrapolating the function of MAO from isolated tissues or animals to humans (3),
The severely impaired deamination of catecholamines in subjects with combined MAO-AB deficiency is demonstrated by the > 9 3 % reductions in plasma concentrations of the deaminated catecholamine metabolites, DHPG, MHPG, and VMA. Additionally, the markedly elevated plasma concentra tions of O-methylated amine metabolites-free and sulfateconjugated normetanephrine and sulfate-conjugated metanephrine-reflect impaired deamination of these metabolites as well as increased availability of the parent amines for O-methylation (14) . Slightly less severe changes in patients with selective MAO-A deficiency and complete lack of similar directional changes in MAO-B-deficient subjects indicate that MAO-A is considerably more important than MAO-B for me tabolism of NE, EPI, and their O-methylated amine metabo lites in vivo. These findings agree with those in rats (14) , where pharmacological inhibition of MAO-B failed to affect either the deaminated or O-methylated amine metabolites of NE and EPI, whereas inhibition of MAO-A resulted in similar direc tional changes to those observed here.
Larger increases in plasma concentrations and urinary ex cretion of normetanephrine than of metanephrine are also in agreement with results in rats or humans administered MAO inhibitors, a difference attributed to little deamination of EPI and metanephrine in the compartment where metanephrine is formed (14, 15) . The larger increases in plasma concentrations of sulfate-conjugated than free metanephrines can be ex plained similarly by compartmentai differences in sites of formation. Over 90% of free metanephrine and a substantial, but lower, portion of free normetanephrine are formed within the adrenals (16, 18) . In contrast, the conjugated metanephrines are not formed within the adrenals, but are formed elsewhere in the body where deamination is a more prominent pathway than in the adrenals.
As previously described (12) , cultured skin fibroblasts of the two subjects with the selective MAO-A deficiency had no MAO-A activity. The present study extends the observation of MAO-A deficiency to the organ level and documents impaired extraneuronal deamination of NE and normetanephrine as in dicated by the increased forearm spillover of normetanephrine from locally released and circulating NE.
According to a study in isolated human brain tissue, DA was proposed as a selective substrate for MAO-B (34) . How ever, studies of substrate specificity of the two forms of MAO in isolated tissues do not always reflect reliably the situation in vivo, and it has now been established that, under physiological conditions, DA is also a substrate for MAO-A (3). The de creases in plasma DOPAC and HVA, decreases in urinary ex cretion of HVA, and increases in urinary excretion of the O-methylated DA metabolite, 3-methoxytyramine, in MAO-A-deficient subjects support an important role for MAO-A in the metabolism of DA. This finding and the complete lack of any similar directional changes in the MAO-B-deficient sub jects are in agreement with the results of individual blockade of the two isoenzymes in rats (14) and raise questions about whether MAO-B has any physiological role in the normal in vivo metabolism of DA.
The substantial decreases in deaminated catecholamine metabolites and increases in O-methylated amine metabolites in MAO-A-deficient but not MAO-B-deficient subjects indi cate that the two isoenzymes do not have equal complemen tary capacities for the deamination of catecholamines when one of the two isoenzymes is lacking. Nevertheless, the some what exaggerated neurochemical changes in patients with com bined MAO-AB deficiency compared with selective MAO-A deficiency indicate that MAO-B plays a minor auxiliary role in the metabolism of catecholamines when the activity of MAO-A is impaired. This conclusion is further supported by the ele vated plasma concentrations and urinary excretion of DA in MAO-AB-deficient subjects, but not in other groups. In rats, combined inhibition of the two MAO isoenzymes reduces the deamination of intravenously infused NE more than inhibition of MAO-A alone, whereas inhibition of MAO-B alone has no effect (14) . The results indicate that, under normal conditions, MAO-B does not have a major role in the deamination of cat echolamines. Normal urinary and platelet levels of 5-HT in MAO-B-deficient subjects and substantial increases in selec tive MAO-A-and combined MAO-AB-deficient subjects also suggest that MAO-B is of less importance than MAO-A for the in vivo metabolism of 5-HT.
An important role for MAO-B is, however, evident for deamination of the trace amines, phenylethylamine and paraand metatyramine. Increased urinary phenylethylamine in MAO-B-deficient subjects represents the only neurochemical abnormality we could detect in these subjects. This increase contrasted with normal urinary phenylethylamine levels in MAO-A-deficient subjects, findings consistent with the reported preferential deamination of phenylethylamine by MAO-B (1, 1016 Lenders et al 33) . The larger increases in phenylethylamine in the individu als with combined MAO-AB deficiencies relative to those with MAO-B deficiency alone indicate that MAO-A can par tially substitute for MAO-B in degrading this trace amine in vivo. In contrast to phenylethylamine, urinary tyramine excre tion was not increased in subjects with selective deficiency of MAO-B or MAO-A but was profoundly increased in MAO-AB-deficient subjects. This confirms that tyramine is a sub strate for both MAO-A and MAO-B (35) and represents one situation in which one isoenzyme is able to compensate fully for the absence of the other. Increased pressor sensitivity to tyramine in the subjects with selective deficiency of MAO-A observed here, in addition to that previously described in MAO-AB-deficient subjects described elsewhere (5) , can be explained by dependence of these sensitivity changes on the capacity to deaminate both tyramine and the NE released from vesicles by tyramine (19) . Predominance of MAO-A within sympathetic neurons (1), where tyramine exerts its pressor actions, is another factor. Normal plasma concentrations of DOPA in MAO-B-deficient subjects and lowered concentrations in subjects with defi ciency of MAO-A, alone or in combination with MAO-B, reflect the important role of MAO-A in the metabolic degradation of NE within the neuronal cytoplasm (1) . As previously demon strated, increased concentrations of NE in the neuronal cytoplasm during inhibition of intraneuronal MAO results in feedback inhibition of tyrosine hydroxylase and decreased for mation and plasma concentrations of the immediate product of the enzyme, DOPA (15, 25, 36) .
The presence of detectable amounts of deaminated metab olites of catecholamines, particularly those of DA, in patients with neither MAO-A nor MAO-B activities indicates that these amines or their O-methylated derivatives are substrates, albeit weak substrates, for other enzymes that degrade amines. Plasma amine oxidase represents one such enzyme that in hu mans can deaminate both DA and its O-methylated metabo lite, 3-methoxytyramine (37, 38) , and which is present at nor mal levels in patients with a lack of MAO isoenzymes.
MAO deficiency and behavior. MAO is a pivotal determi nant in the metabolism of amines that affect behavior and mood; pharmacological inhibition of MAO in animals and hu mans has profound effects on neurophysiological functioning (39, 40) . Consequently, it has been assumed that genetically determined variations of MAO activity might be associated with behavioral and mood disorders. Numerous cross-sec tional studies have established an association between low platelet MAO-B activity and pathological behavior (41-43); a causal relation, however, has never been established. A lack of correlation in MAO-B activity between platelets and brain has been suggested (44) . However, the amino acid sequences are identical (45) , and the biochemical and pharmacological char acteristics of the isoenzyme in the two tissues are also similar (35) , excluding a genetically encoded difference in the struc ture of the MAO-B isoenzyme between these tissues.
The present study shows that lack of MAO-B is associated with apparently normal behavior, whereas a lack of MAO-A is not (11, 12) . In addition, the metabolic data in the MAO-Bdeficient subjects indicate that an impairment in the break down of phenylethylamine is not related to abnormal behav ior. Normal phenylethylamine excretion in the selective MAO-A-deficient subjects further suggests that this trace amine is unlikely to be involved in the behavioral disorders that characterize these patients.. These data do not, however, exclude a possible neuromodulatory function of phenylethyl amine in central nervous system catecholamine systems (46) .
Despite the predominance of MAO-B over MAO-A in the human brain (3), the prominent disturbances in behavior in MAO-A-deficient subjects and the normal behavior in MAO-B-deficient subjects indicate that MAO-A plays a more vital role than MAO-B in the normal neurophysiological develop ment and function. This conclusion is consistent with the con siderably more important role of MAO-A compared with MAO-B in the metabolism of catecholamines and 5-HT re vealed by the present study. However, whether any of the profound neurochemical derangements observed in MAO-Adeficient subjects reflect the physiological basis of the behav ioral disorder in these subjects remains to be established.
A relationship between the observed neurochemical and behavioral abnormalities in MAO-A-deficient subjects is strongly supported by a recent study in transgenic mice with a deletion in the MAO-A gene (47) . The severe behavioral dis turbances in these animals were associated with markedly ele vated brain 5-HT concentrations and could be reversed by postnatal administration of a 5-HT synthesis inhibitor. A causal relationship between altered 5-HT metabolism and dis turbed behavior was suggested to be mediated by discrete cor tical alterations induced by chronically elevated 5-HT levels. Further support for involvement of altered 5-HT metabolism is provided by another recent study, in which behavioral dis turbances in rats administered MAO inhibitors, before and af ter birth, were also associated with structural changes in brain serotoninergic systems (48) . We have previously argued that the possible disruptive effect of raised 5-HT levels on the de veloping brain may help explain why impulsive aggressive be havior has been consistently associated with low levels of 5-HT or its primary metabolite, 5-hydroxyindol acetic acid, whereas 5-HT levels are elevated in subjects with selective MAO-A de ficiency who show similar behavior (49) .
The patients with combined deletions of the MAO-A and MAO-B genes also have deletions of the Norrie disease gene. However, the severe neurological symptoms and mental retar dation in these patients are not universal characteristics of pa tients with Norrie disease (8, 16) . This is illustrated by the present patients with deletions of the MAO-B and Norrie dis ease genes, both of whom had completed university degrees and in whom the only symptoms were the early onset blind ness and impaired hearing. Despite the essentially normal neu rochemical profile in MAO-B-deficient patients, those with combined MAO-AB deficiency had somewhat more severe neurochemical changes than MAO-A-deficient patients, sug gesting that MAO-B may compensate, albeit to a limited ex tent, for lack of MAO-A. Thus, it is possible that the much more severe mental retardation and other neurological abnor malities observed in patients with combined MAO-AB (com pared with selective MAO-A deficiency) are due to additional deletion of the MAO-B gene. However, since the patients with combined MAO-AB deficiency have deletions of various sizes that possibly involve other genes on the X chromosome, other explanations should also be considered.
Neurochemical phenotyping may provide a sensitive tool for detection of the MAO-A deficiency state. In contrast to la borious methods of direct DNA analysis and measurements of fibroblast MAO-A activities, measurement of plasma cate cholamine metabolites provides a relatively simple screening procedure. In particular, use of the ratio of plasma concentra tions of sulfate-conjugated normetanephrine to plasma DHPG, which are the metabolites that show the most dramatic changes, provides a sensitive method for the detection of subjects sus pected of having reduced activity of MAO-A.
In conclusion, selective deficiency of MAO-B does not lead to a specific clinical phenotype and, in particular, is not associ ated with clinically apparent disturbances in behavior such as are observed in deficiencies of MAO-A, The absence in MAO-B-deficient patients of the severe neurochemical alter ations observed in patients with deficiencies of MAO-A or MAO-AB indicates that MAO-A is considerably more impor tant than MAO-B for metabolism of most biogenic amines. These functional differences in the two isoenzymes of MAO are likely to contribute to the different clinical phenotypes ob served in patients with deficiencies of either or both isoen zymes and may help in understanding the basis for therapeutic interventions involving specific inhibition of one or the other isoenzymes.
